Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program

Press Releases

Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127

Rehovot, Israel – November 12, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today positive preliminary results from recently completed animal studies in its immuno-oncology program,